NCT06276010

Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO

Use of Nafamostat Mesilate for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation After Cardiac Surgery: Efficacy and Safety

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Xiaotong Hou · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the effectiveness and safety of nafamostat mesilate compared with unfractionated heparin for anticoagulation in patients with ECMO after cardiac surgery.

Detailed description

Selecting patients who require systemic anticoagulation as the study subjects from patients undergoing extracorporeal membrane oxygenation assistance after cardiac surgery. Randomly divided into the nafamostat mesilate group and unfractionated heparin group. To evaluate the efficacy and safety of nafamostat mesilate by comparing the incidence of bleeding and thrombosis within the target anticoagulant level range between two groups of patients during ECMO

Conditions

• Extracorporeal Membrane Oxygenation Complication

Interventions

Type	Name	Description
DRUG	nafamostat mesilate	Use nafamostat mesilate as an anticoagulant
DRUG	unfractionated heparin group	Use unfractionated heparin as an anticoagulant

Timeline

• Start date: 2024-07-01
• Primary completion: 2026-11-01
• Completion: 2026-12-31
• First posted: 2024-02-23
• Last updated: 2025-09-25

Locations

1 site across 1 country: China